Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.22 EPS

Mirum Pharmaceuticals (NASDAQ:MIRM) posted its quarterly earnings results on Wednesday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22), Zacks reports. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals updated its FY 2025 guidance to EPS.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM traded up $0.54 during midday trading on Friday, hitting $47.52. 64,607 shares of the stock were exchanged, compared to its average volume of 527,628. Mirum Pharmaceuticals has a one year low of $23.14 and a one year high of $54.23. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -23.52 and a beta of 0.96. The business has a 50-day moving average price of $46.84 and a two-hundred day moving average price of $43.35. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Wall Street Analyst Weigh In

A number of brokerages have commented on MIRM. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday. HC Wainwright lifted their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday. Finally, Citigroup lifted their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $58.20.

Insider Buying and Selling

In related news, COO Peter Radovich sold 1,998 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36. Following the sale, the chief operating officer now owns 27,015 shares of the company’s stock, valued at $1,156,782.30. The trade was a 6.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares in the company, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,915 shares of company stock valued at $1,897,920 over the last quarter. Corporate insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.